Title
Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study
Date Issued
01 January 2021
Access level
open access
Resource Type
journal article
Author(s)
Dawood F.S.
Kittikraisak W.
Patel A.
Rentz Hunt D.
Suntarattiwong P.
Wesley M.G.
Thompson M.G.
Soto G.
Mundhada S.
Arriola C.S.
Azziz-Baumgartner E.
Brummer T.
Cabrera S.
Chang H.H.
Deshmukh M.
Ellison D.
Florian R.
Gonzales O.
Kurhe K.
Kaoiean S.
Rawangban B.
Lindstrom S.
Llajaruna E.
Mott J.A.
Saha S.
Prakash A.
Mohanty S.
Sinthuwattanawibool C.
US Naval Medical Research
Publisher(s)
Lancet Publishing Group
Abstract
Background: Influenza vaccination during pregnancy prevents influenza among women and their infants but remains underused among pregnant women. We aimed to quantify the risk of antenatal influenza and examine its association with perinatal outcomes. Methods: We did a prospective cohort study in pregnant women in India, Peru, and Thailand. Before the 2017 and 2018 influenza seasons, we enrolled pregnant women aged 18 years or older with expected delivery dates 8 weeks or more after the season started. We contacted women twice weekly until the end of pregnancy to identify illnesses with symptoms of myalgia, cough, runny nose or nasal congestion, sore throat, or difficulty breathing and collected mid-turbinate nasal swabs from symptomatic women for influenza real-time RT-PCR testing. We assessed the association of antenatal influenza with preterm birth, late pregnancy loss (≥13 weeks gestation), small for gestational age (SGA), and birthweight of term singleton infants using Cox proportional hazards models or generalised linear models to adjust for potential confounders. Findings: Between March 13, 2017, and Aug 3, 2018, we enrolled 11 277 women with a median age of 26 years (IQR 23–31) and gestational age of 19 weeks (14–24). 1474 (13%) received influenza vaccines. 310 participants (3%) had influenza (270 [87%] influenza A and 40 [13%] influenza B). Influenza incidences weighted by the population of women of childbearing age in each study country were 88·7 per 10 000 pregnant woman-months (95% CI 68·6 to 114·8) during the 2017 season and 69·6 per 10 000 pregnant woman-months (53·8 to 90·2) during the 2018 season. Antenatal influenza was not associated with preterm birth (adjusted hazard ratio [aHR] 1·4, 95% CI 0·9 to 2·0; p=0·096) or having an SGA infant (adjusted relative risk 1·0, 95% CI 0·8 to 1·3, p=0·97), but was associated with late pregnancy loss (aHR 10·7, 95% CI 4·3 to 27·0; p<0·0001) and reduction in mean birthweight of term, singleton infants (−55·3 g, 95% CI −109·3 to −1·4; p=0·0445). Interpretation: Women had a 0·7–0·9% risk of influenza per month of pregnancy during the influenza season, and antenatal influenza was associated with increased risk for some adverse pregnancy outcomes. These findings support the added value of antenatal influenza vaccination to improve perinatal outcomes. Funding: US Centers for Disease Control and Prevention. Translations: For the Thai, Hindi, Marathi and Spanish translations of the abstract see Supplementary Materials section.
Start page
97
End page
106
Volume
21
Issue
1
Language
English
OCDE Knowledge area
Epidemiología
Obstetricia, Ginecología
Scopus EID
2-s2.0-85096025115
PubMed ID
Source
The Lancet Infectious Diseases
ISSN of the container
14733099
Sponsor(s)
This study was funded by the US Centers for Disease Control and Prevention through the following funding mechanisms: Cooperative Agreement 1U01GH002084 with Thailand Ministry of Public Health, Interagency Agreements 16FED1612328, 17FED1712076, and 18FED1812054IPD with the US Naval Medical Research Unit No 6, and Contract HHSD2002013M53890B with Abt Associates. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the US Government. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human participants as prescribed in AR 70?25. FSD, WK, MGT, GS, CSA, EA-B, DE, SL, JAM, SS, CS, and YT are employees of the US Government. This work was prepared as part of their official duties. Title 17 USC ? 105 provides that ?Copyright protection under this title is not available for any work of the United States Government?. Title 17 USC ? 101 defines a US Government work as a work prepared by a military service member or employee of the LUSTER-1 and LUSTER-2 as part of that person's official duties. The authors wish to acknowledge Eric Griggs at the Centers for Disease Control and Prevention for analytic support.
Sources of information:
Directorio de Producción Científica
Scopus